Oncological and functional outcomes following transoral laser microsurgery in patients with T2a vs T2b glottic squamous cell carcinoma.
Functional outcomes
Glottic cancer
T2 glottic
Transoral laser microsurgery
Vocal cord mobility
Journal
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
ISSN: 1916-0216
Titre abrégé: J Otolaryngol Head Neck Surg
Pays: England
ID NLM: 101479544
Informations de publication
Date de publication:
07 Jun 2019
07 Jun 2019
Historique:
received:
05
04
2018
accepted:
21
05
2019
entrez:
9
6
2019
pubmed:
9
6
2019
medline:
17
1
2020
Statut:
epublish
Résumé
There is a paucity of evidence comparing oncological and voice outcomes between T2a and T2b glottic squamous cell carcinoma (SCC) patients treated with transoral laser microsurgery (TLM). This study identified functional and oncological outcomes in this cohort. Retrospective review of prospectively collected data of patients treated with TLM for T2 glottic SCC from 2003 to 2017. In total, 75 patients were included. Five-year local control rates were significantly different between T2a and T2b patients (75.2% vs 57.0%, p = 0.022). There was no difference in five-year survival between patients with T2a disease and T2b disease (69.5% vs 73.4%, p = 0.627). There was no significant difference in mean VHI-10 scores in the pre-operative period (18.3 vs 21.4, p = 0.409). However, patients with T2b disease had significantly worse perceived voice outcomes post-operatively (6.6 vs 21.3 p = 0.001). Patients with T2a disease saw significant improvements in mean VHI-10 scores following surgery (18.3 vs 6.6, p = 0.000), while T2b patients did not (21.4 vs 21.3, p = 0.979). The overall laryngeal preservation rate was 94.7%, with 11.5% of T2b patients requiring salvage organ sacrifice. This study highlights positive functional outcomes for T2a glottic SCC. Patients with T2b disease appear to have significantly worse oncological and functional outcomes, including worse voice quality following surgery and higher rates of salvage laryngectomy.
Sections du résumé
BACKGROUND
BACKGROUND
There is a paucity of evidence comparing oncological and voice outcomes between T2a and T2b glottic squamous cell carcinoma (SCC) patients treated with transoral laser microsurgery (TLM). This study identified functional and oncological outcomes in this cohort.
METHODS
METHODS
Retrospective review of prospectively collected data of patients treated with TLM for T2 glottic SCC from 2003 to 2017.
RESULTS
RESULTS
In total, 75 patients were included. Five-year local control rates were significantly different between T2a and T2b patients (75.2% vs 57.0%, p = 0.022). There was no difference in five-year survival between patients with T2a disease and T2b disease (69.5% vs 73.4%, p = 0.627). There was no significant difference in mean VHI-10 scores in the pre-operative period (18.3 vs 21.4, p = 0.409). However, patients with T2b disease had significantly worse perceived voice outcomes post-operatively (6.6 vs 21.3 p = 0.001). Patients with T2a disease saw significant improvements in mean VHI-10 scores following surgery (18.3 vs 6.6, p = 0.000), while T2b patients did not (21.4 vs 21.3, p = 0.979). The overall laryngeal preservation rate was 94.7%, with 11.5% of T2b patients requiring salvage organ sacrifice.
CONCLUSIONS
CONCLUSIONS
This study highlights positive functional outcomes for T2a glottic SCC. Patients with T2b disease appear to have significantly worse oncological and functional outcomes, including worse voice quality following surgery and higher rates of salvage laryngectomy.
Identifiants
pubmed: 31174618
doi: 10.1186/s40463-019-0346-7
pii: 10.1186/s40463-019-0346-7
pmc: PMC6556033
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Références
Laryngoscope. 2004 Sep;114(9):1549-56
pubmed: 15475780
J Laryngol Otol. 1992 Mar;106(3):197-204
pubmed: 1564374
Clin Otolaryngol. 2005 Feb;30(1):42-7
pubmed: 15748189
J Otolaryngol. 2006 Dec;35(6):413-9
pubmed: 17380837
Eur Arch Otorhinolaryngol. 2008 May;265(5):543-8
pubmed: 17999074
Arch Otolaryngol Head Neck Surg. 2009 May;135(5):479-86
pubmed: 19451470
Clin Otolaryngol. 2010 Oct;35(5):373-82
pubmed: 21108747
Head Neck. 2014 Jun;36(6):859-66
pubmed: 23720321
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):958-963
pubmed: 25035199
J Laryngol Otol. 2016 May;130(S2):S75-S82
pubmed: 27841116
Clin Otolaryngol. 2017 Jun;42(3):629-636
pubmed: 27863075
Ann Otol Rhinol Laryngol. 1967 Jun;76(2):313-29
pubmed: 6028661
Cancer. 1980 Mar 1;45(5):991-5
pubmed: 7260851